Since 1990, helping busy clinicians master the science and art of caring for people with HIV disease.

Latest News

Tuesday, March 6, 2012

Intracellular drug levels and PrEP dosing strategies


PRN Report from 19th CROI:

In a late breaker, Peter Anderson of the University of Colorado Denver reported on a substudy of the iPrEx trial (which has already demonstrated a 42% decrease in HIV acquisition in men who have sex with men (MSM) assigned to daily oral emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) versus placebo, with ~90% risk reduction estimated for those with drug detected in blood), in which intracellular drug concentrations associated with pre-exposure prophylaxis (PrEP) efficacy in iPrEx, were used to identify dosing regimens likely to achieve high efficacy.

HIV-uninfected active-arm controls were matched to each active-arm HIV-infected case, plasma and/or viably cryopreserved peripheral blood mononuclear cells (v-PBMC) were tested from all available time points; every 3 months for plasma, every 6 months for v-PBMC, and at HIV seroconversion in cases. Multiple imputation inferred drug levels for all active-arm participants based on observed concentrations and subject characteristics. A Cox model was used to estimate HIV incidence relative to placebo with tenofovir-diphosphate (TFV-DP) as a time-dependent covariate. The predicted HIV risk reduction was then estimated for TFV-DP levels (in v-PBMC) arising from 3 dosing strategies from STRAND, a randomized, crossover trial of oral TDF in 23 HIV– subjects assigned to 2, 4, and 7 doses per week (directly observed), for 6 weeks at each dose.

Six hundred and fifteen v-PBMC and 1146 plasma samples were tested from 1212 time points (302 cases, 910 controls). The risk of contracting HIV was reduced by ≥90% relative to placebo among those with a TFV-DP concentration ≥15.6 fmol/M viable cells (95%CI 3.0 to 28.2). Based on this model, estimated HIV risk reduction associated with TFV-DP troughs (median [IQR]) generated in STRAND was 76% for 2 doses per week, 97% for 4 doses per week and 99% for 7 doses per week.

Dr Anderson concluded that an intracellular TFV-DP concentration of 15.6 fmol/M viable cells was associated with 90% reduced risk of HIV acquisition relative to placebo among MSM. Daily and 4 doses per week of oral TDF produced TFV-DP concentrations corresponding with high PrEP efficacy.

Reference:
Anderson P, Liu A, Buchbinder S, et al. Intracellular Tenofovir-DP Concentrations Associated with PrEP Efficacy in MSM from iPrEx. Presented March 6, 2012 at the 19th CROI, Seattle, WA. Oral Abstract #31LB.


Source: Reporting from Seattle for PRN News: James Braun, DO